![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » SAMARITAN IN-LICENSES GREECE & CYPRUS MARKETING RIGHTS FOR AMPHOCIL FROM THREE RIVERS
SAMARITAN IN-LICENSES GREECE & CYPRUS MARKETING RIGHTS FOR AMPHOCIL FROM THREE RIVERS
December 14, 2005
Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today its European subsidiary, Samaritan Europe has entered into an exclusive distribution agreement with Three Rivers Pharmaceuticals for the marketing and sales of Amphocil(R) (amphotericin B cholesteryl sulfate complex for injection) in Greece and Cyprus. Amphocil is indicated for the treatment of invasive aspergillosis, a fungal infection that occurs in immuno-compromised patients.
Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1126366XSL_NEWSML_TO_NEWSML_WEB.xml)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct